Targeting a specific receptor to fight pancreatic cancer spread
Targeting pancreatic cancer metastases with Targefrin
This study is testing a new treatment for metastatic pancreatic cancer that targets a specific protein on cancer cells to help stop their spread and deliver chemotherapy directly to the tumors, aiming to improve outcomes for patients like you.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Armida Labs, INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11073471 on NIH RePORTER |
What this research studies
This research focuses on a novel treatment strategy for metastatic pancreatic cancer by targeting the EphA2 receptor, which is commonly found on these cancer cells. The approach involves using a newly developed agent that not only inhibits the movement and invasion of cancer cells but also helps deliver chemotherapy directly to the tumors. By conducting both cellular studies and in vivo models, the research aims to demonstrate the effectiveness of this agent in reducing cancer spread and improving treatment outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with metastatic pancreatic cancer who have high levels of the EphA2 receptor.
Not a fit: Patients with non-metastatic pancreatic cancer or those without the EphA2 receptor may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research targeting similar cancer receptors has shown promising results, indicating potential for success with this novel approach.
Where this research is happening
San Diego, United States
- Armida Labs, INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Baggio, Carlo — Armida Labs, INC.
- Study coordinator: Baggio, Carlo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.